269 related articles for article (PubMed ID: 38566153)
1. Super enhancer lncRNAs: a novel hallmark in cancer.
Song P; Han R; Yang F
Cell Commun Signal; 2024 Apr; 22(1):207. PubMed ID: 38566153
[TBL] [Abstract][Full Text] [Related]
2. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
[TBL] [Abstract][Full Text] [Related]
3. SELER: a database of super-enhancer-associated lncRNA- directed transcriptional regulation in human cancers.
Guo ZW; Xie C; Li K; Zhai XM; Cai GX; Yang XX; Wu YS
Database (Oxford); 2019 Jan; 2019():. PubMed ID: 30806704
[TBL] [Abstract][Full Text] [Related]
4. [Research progress of super enhancer in cancer].
Wu ZQ; Mi ZY
Yi Chuan; 2019 Jan; 41(1):41-51. PubMed ID: 30686784
[TBL] [Abstract][Full Text] [Related]
5. Characterization of super-enhancer-associated functional lncRNAs acting as ceRNAs in ESCC.
Wang QY; Peng L; Chen Y; Liao LD; Chen JX; Li M; Li YY; Qian FC; Zhang YX; Wang F; Li CQ; Lin DC; Xu LY; Li EM
Mol Oncol; 2020 Sep; 14(9):2203-2230. PubMed ID: 32460441
[TBL] [Abstract][Full Text] [Related]
6. Super-enhancers complexes zoom in transcription in cancer.
Wang M; Chen Q; Wang S; Xie H; Liu J; Huang R; Xiang Y; Jiang Y; Tian D; Bian E
J Exp Clin Cancer Res; 2023 Jul; 42(1):183. PubMed ID: 37501079
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors.
Li XP; Qu J; Teng XQ; Zhuang HH; Dai YH; Yang Z; Qu Q
Int J Biol Sci; 2023; 19(4):1036-1048. PubMed ID: 36923930
[TBL] [Abstract][Full Text] [Related]
8. Super-lncRNAs: identification of lncRNAs that target super-enhancers via RNA:DNA:DNA triplex formation.
Soibam B
RNA; 2017 Nov; 23(11):1729-1742. PubMed ID: 28839111
[TBL] [Abstract][Full Text] [Related]
9. LncRNA Platr22 promotes super-enhancer activity and stem cell pluripotency.
Yan P; Lu JY; Niu J; Gao J; Zhang MQ; Yin Y; Shen X
J Mol Cell Biol; 2021 Aug; 13(4):295-313. PubMed ID: 33049031
[TBL] [Abstract][Full Text] [Related]
10. Super-enhancers: A new frontier for glioma treatment.
Cheng M; Zhang ZW; Ji XH; Xu Y; Bian E; Zhao B
Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188353. PubMed ID: 32112817
[TBL] [Abstract][Full Text] [Related]
11. Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies.
Dębek S; Juszczyński P
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188697. PubMed ID: 35150791
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
[TBL] [Abstract][Full Text] [Related]
13. Super-enhancers and novel therapeutic targets in colorectal cancer.
Liu Q; Guo L; Lou Z; Xiang X; Shao J
Cell Death Dis; 2022 Mar; 13(3):228. PubMed ID: 35277481
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression.
Yang Z; Zheng Y; Wu H; Xie H; Zhao J; Chen Z; Li L; Yue X; Zhao B; Bian E
Hum Genomics; 2023 Mar; 17(1):33. PubMed ID: 37004060
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms.
Jia Q; Chen S; Tan Y; Li Y; Tang F
Exp Mol Med; 2020 May; 52(5):713-723. PubMed ID: 32382065
[TBL] [Abstract][Full Text] [Related]
16. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma.
Yuan XQ; Zhou N; Wang JP; Yang XZ; Wang S; Zhang CY; Li GC; Peng L
Mol Ther; 2023 Jun; 31(6):1756-1774. PubMed ID: 36461633
[TBL] [Abstract][Full Text] [Related]
17. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
18. The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino S; Suzuki HI
Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
[TBL] [Abstract][Full Text] [Related]
19. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
20. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
Bacabac M; Xu W
Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
